
FNC Biotech
Antibody therapeutics developer for incurable diseases.
Date | Investors | Amount | Round |
---|---|---|---|
* | KRW2.0b | Series A | |
Total Funding | 000k |
FNCT Biotech is a biopharmaceutical company developing antibody-based therapies for diseases with significant unmet medical needs, with a primary focus on idiopathic pulmonary fibrosis (IPF). The company is advancing a treatment candidate that targets the underlying cause of IPF. This novel therapy is based on a paradigm where CSF3 is identified as the upstream pathway regulating key fibrosis pathways, including TGF-β.
The company's approach has an established proof-of-concept and a defined mechanism of action, demonstrating therapeutic potential. Based in Seoul, South Korea, FNCT Biotech was founded in November 2021. Its mission is to develop solutions that improve lives in a responsible and sustainable manner, with a focus on providing hope for patients with incurable diseases through innovative medical research and development.
The company's business model is centered on advancing its antibody drug pipeline to deliver clinical benefits and commercial value. FNCT Biotech has secured funding from investors including BSK Investment, Industrial Bank of Korea, Meritz Securities, Premier Partners, and the Tech Incubator Program for Startup. In October 2023, it raised KRW 2.0 billion in a Series A round from Meritz Securities.
Keywords: antibody therapeutics, idiopathic pulmonary fibrosis, drug development, biopharmaceutical, fibrosis treatment, CSF3 pathway, TGF-β, antibody drug, incurable diseases, medical research, life sciences, biotechnology, pulmonary fibrosis care, drug delivery, preclinical